Skip to main content

Incyte Corporation (INCY)

NASDAQ: INCY · IEX Real-Time Price · USD
67.33 0.60 (0.90%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap14.87B
Revenue (ttm)2.91B
Net Income (ttm)534.58M
Shares Out220.89M
EPS (ttm)2.41
PE Ratio27.91
Forward PE16.45
Dividendn/a
Ex-Dividend Daten/a
Volume960,837
Open66.95
Previous Close66.73
Day's Range65.95 - 67.50
52-Week Range61.91 - 101.47
Beta0.72
AnalystsBuy
Price Target93.13 (+38.3%)
Earnings DateNov 2, 2021

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitin...

IndustryBiotechnology
IPO DateNov 4, 1993
CEOPaul Friedman
Employees1,773
Stock ExchangeNASDAQ
Ticker SymbolINCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for Incyte stock is "Buy." The 12-month stock price forecast is 93.13, which is an increase of 38.32% from the latest price.

Price Target
$93.13
(38.32% upside)
Analyst Consensus: Buy

News

Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

6 days ago - Zacks Investment Research

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients wit...

INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who recei...

Other symbols:LLY
4 weeks ago - PRNewsWire

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference

4 weeks ago - Business Wire

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

Other symbols:AMGNBIIBGILDREGN
1 month ago - Kiplinger

Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based The...

HOUSTON and SHANGHAI, Nov. 4, 2021 /PRNewswire/ -- Cellenkos ®  Inc. ("Cellenkos"), a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune an...

1 month ago - PRNewsWire

More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH21--More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition.

1 month ago - Business Wire

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

1 month ago - Zacks Investment Research

Incyte (INCY) Q3 Earnings and Revenues Beat Estimates

Incyte (INCY) delivered earnings and revenue surprises of 55.26% and 8.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

1 month ago - Business Wire

Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle ce...

1 month ago - Benzinga

Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 202...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

1 month ago - Business Wire

Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

1 month ago - Business Wire

Should You Buy Incyte Corporation (INCY) Ahead of Earnings?

Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?

Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.

1 month ago - Zacks Investment Research

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

1 month ago - Business Wire

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

It's much too early to count these companies out.

Other symbols:GILD
1 month ago - The Motley Fool

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Why the Earnings Surprise Streak Could Continue for Incyte (INCY)

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

There's Money to Be Made With Vertex, Viatris, Incyte and Biogen

A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pharm...

Other symbols:BIIBVTRS
1 month ago - GuruFocus

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

1 month ago - Zacks Investment Research

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Third Quarter Financial Results

1 month ago - Business Wire

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With V...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADVCongress--Incyte Announces Full Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients with Vitiligo

2 months ago - Business Wire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs...

Other symbols:GMABSGENTAK
2 months ago - Benzinga

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Compl...

INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which...

Other symbols:LLY
2 months ago - PRNewsWire

Incyte Names New Member to Its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Names New Member to Its Board of Directors

2 months ago - Business Wire